American Well (NYSE:AMWL – Get Free Report) and iRhythm Technologies (NASDAQ:IRTC – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Valuation & Earnings
This table compares American Well and iRhythm Technologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| American Well | $254.36 million | 0.31 | -$208.14 million | ($7.20) | -0.68 |
| iRhythm Technologies | $591.84 million | 8.73 | -$113.29 million | ($1.61) | -99.59 |
Institutional and Insider Ownership
56.1% of American Well shares are owned by institutional investors. 12.8% of American Well shares are owned by company insiders. Comparatively, 0.7% of iRhythm Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for American Well and iRhythm Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| American Well | 1 | 6 | 1 | 0 | 2.00 |
| iRhythm Technologies | 1 | 1 | 11 | 2 | 2.93 |
American Well presently has a consensus target price of $7.58, suggesting a potential upside of 55.36%. iRhythm Technologies has a consensus target price of $219.23, suggesting a potential upside of 36.73%. Given American Well’s higher possible upside, research analysts clearly believe American Well is more favorable than iRhythm Technologies.
Risk & Volatility
American Well has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
Profitability
This table compares American Well and iRhythm Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| American Well | -42.80% | -39.80% | -29.38% |
| iRhythm Technologies | -7.32% | -41.86% | -4.42% |
Summary
iRhythm Technologies beats American Well on 9 of the 15 factors compared between the two stocks.
About American Well
American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members. It provides Carepoint devices comprising carts, peripherals, tablets, and TVs, which serve as digital access points in clinical settings. In addition, the company offers Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, acute psychiatry, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.
About iRhythm Technologies
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Receive News & Ratings for American Well Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Well and related companies with MarketBeat.com's FREE daily email newsletter.
